XBiotech (XBIT) Short term Debt (2024)

XBiotech (XBIT) posted Short term Debt of $10.0 million for Q4 2024, little changed on a QoQ basis from $10.0 million in Q3 2024.

Analysis

XBiotech (XBIT) Short term Debt (2024) Analysis & Trends

XBiotech has reported Short term Debt for 1 years, with the latest figure at $10.0 million in Q4 2024.

On a quarterly basis, Short term Debt changed N/A year-over-year to $10.0 million in Q4 2024; TTM through Dec 2024 was $10.0 million, a N/A change from a year earlier, with the FY2024 full-year figure at $10.0 million, changed N/A from the prior year.
Short term Debt was $10.0 million for Q4 2024 at XBiotech, roughly flat from $10.0 million in the prior quarter.
The five-year high for Short term Debt was $10.0 million in Q1 2024, with the low at $10.0 million in Q1 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	236.37 Bn	222.38 Bn	7.24 Bn
2	Gilead Sciences	187.38 Bn	184.12 Bn	6.22 Bn
3	Vertex Pharmaceuticals	138.36 Bn	130.51 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	85.09 Bn	77.10 Bn	3.93 Bn
5	Argenx Se	63.93 Bn	58.75 Bn	1.37 Bn
6	Moderna	58.07 Bn	52.94 Bn	52.00 Mn
7	Alnylam Pharmaceuticals	35.59 Bn	32.28 Bn	992.69 Mn
8	Biogen	32.63 Bn	31.34 Bn	1.96 Bn
9	Insmed	27.57 Bn	26.41 Bn	358.27 Mn
10	XBiotech	67.07 Mn	67.07 Mn	-

Historic Data

Download Data